Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Sarepta Therapeutics (SRPT)

Sarepta Q4 revenue falls 33% to $442.9 million; net loss of $412.2 million

Mixed Impact 4 of 5 earnings Written later

Sarepta reported fourth-quarter 2025 total revenues of $442.9 million, down 33% from $658.4 million a year earlier, and a GAAP net loss of $412.2 million, compared with net income of $159.0 million in the prior-year quarter. For the full year, revenues rose 16% to $2,198.2 million, but the GAAP net loss was $713.4 million, compared with net income of $235.2 million in 2024.

Key points

  • Q4 2025 total revenues were $442.9 million versus $658.4 million in Q4 2024, mainly due to $273.8 million less ELEVIDYS net product revenue after the June 2025 suspension of shipments to non-ambulatory patients in the U.S.
  • Q4 2025 GAAP net loss was $412.2 million, or $3.93 per diluted share, including a $165.3 million increase in an inventory valuation reserve.
  • Full-year 2025 GAAP net loss was $713.4 million, or $7.13 per diluted share, versus net income of $235.2 million, or $2.34 per share, in 2024.
  • Cash, cash equivalents, restricted cash and investments were $953.8 million as of December 31, 2025, down from $1,503.5 million a year earlier.

The filing

CompanySarepta Therapeutics (SRPT)
Form8-K, current report
Filed with the SECFeb 25, 2026, 4:10 PM ET
Accession number0001193125-26-071566

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:54 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 25, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.